
US stocks rally to records on hopes for cuts to interest rates
The S&P 500 rose 1.1% to top its all-time high set two weeks ago. The Dow Jones Industrial Average climbed 483 points, or 1.1%, and the Nasdaq composite jumped 1.4% to set its own record.
Stocks got a lift from hopes that the better-than-expected inflation report will give the Federal Reserve leeway to cut interest rates at its next meeting in September.
Lower rates would give a boost to investment prices and to the economy by making it cheaper for U.S. households and businesses to borrow to buy houses, cars or equipment. President Donald Trump has angrily been calling for cuts to help the economy, often insulting the Fed's chair personally while doing so.
But the Fed has been hesitant because of the possibility that Trump's tariffs could make inflation much worse. Lowering rates would give inflation more fuel, potentially adding oxygen to a growing fire. That's why Fed officials have said they wanted to see more data come in about inflation before moving.
Tuesday's report said U.S. consumers paid prices for groceries, gasoline and other costs of living that were overall 2.7% higher in July than a year earlier. That's the same inflation rate as June's, and it was below the 2.8% that economists expected.
The report pushed traders on Wall Street to increase bets that the Fed will cut interest rates for the first time this year in September. They're betting on a 94% chance of that, up from nearly 86% a day earlier, according to data from CME Group.
The Fed will receive one more report on inflation, as well as one more on the U.S. job market, before its next meeting, which ends Sept. 17. The most recent jobs report was a stunner, coming in much weaker than economists expected.
Some economists warn that more twists and turns in upcoming data could make the Fed's upcoming decisions not so easy. Its twin goals are to get inflation to 2% while keeping the job market healthy. Helping one with interest rates, though, often means hurting the other.
Even Tuesday's better-than-expected inflation report had some discouraging undertones. An underlying measure of inflation, which economists say does a better job of predicting where inflation may be heading, hit its highest point since early this year, noted Gary Schlossberg, market strategist at Wells Fargo Investment Institute. That helped cause some up-and-down swings for Treasury yields in the bond market.
'Eventually, tariffs can show up in varying degrees in consumer prices, but these one-off price increases don't happen all at once,' said Brian Jacobsen, chief economist at Annex Wealth Management. 'That will confound the Fed and economic commentators for months to come.'
Other central banks around the world have been lowering interest rates, and Australia's on Tuesday cut for the third time this year.
On Wall Street, Intel's stock rose 5.6% after Trump said its CEO has an 'amazing story,' less than a week after he had demanded Lip-Bu Tan's resignation.
Circle Internet Group, the company behind the popular USDC cryptocurrency that tracks the U.S. dollar, climbed 1.3% despite reporting a larger loss for the latest quarter than analysts expected. It said its total revenue and reserve income grew 53% in its first quarter as a publicly traded company, which topped forecasts.
On the losing side of Wall Street was Celanese, which sank 13.1% even though the chemical company delivered a better profit than expected. It said that customers in most of its markets continue to be challenged, and CEO Scott Richardson said that 'the demand environment does not seem to be improving.'
Cardinal Health dropped 7.2% despite likewise reporting a stronger profit for the latest quarter than analysts expected. Its revenue fell short of forecasts, and analysts said the market's expectations were particularly high for the company after its stock had already soared 33.3% for the year coming into the day.
Critics say the broad U.S. stock market is looking expensive after its surge from a bottom in April. That's putting pressure on companies to deliver continued growth in profit.
All told, the S&P 500 rose 72.31 points to 6,445.76. The Dow Jones Industrial Average climbed 483.52 to 44,458.61, and the Nasdaq composite jumped 296.50 to 21,681.90.
In stock markets abroad, indexes edged up in China after Trump signed an executive order late Monday that delayed hefty tariffs on the world's second-largest economy by 90 days. The move was widely expected, and the hope is that it will clear the way for a possible deal to avert a dangerous trade war between the United States and China.
Japan's Nikkei 225 jumped 2.1%, and South Korea's Kospi fell 0.5% for two of the world's bigger moves.
In the bond market, the yield on the 10-year Treasury rose to 4.28% from 4.27% late Monday.
The yield on the two-year Treasury, which more closely tracks expectations for the Fed, fell to 3.73% from 3.76%.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
2 minutes ago
- Cision Canada
Biotech Stocks Rally as Oncology Market Targets $866B by 2034
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /CNW/ -- Equity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears that the private sector continues to step up, with hundreds of millions of VC dollars pouring into oncology ventures so far in 2025. While there has been a recent victory in the Senate to restore $15 million for the Pancreatic Cancer Research Program (PCARP), the prior elimination of the only federal program dedicated solely to researching pancreatic cancer served as a stark reminder of these ongoing funding challenges. This dynamic is setting the stage for a "flight to quality" among investors, who are now more than ever looking for innovative leaders with strong pipelines and clear paths to regulatory execution, a key milestone that can separate a promising biotech from a potential breakthrough like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), ProPhase Labs, Inc. (NASDAQ: PRPH), IO Biotech, Inc. (NASDAQ: IOBT), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), and PDS Biotechnology Corporation (NASDAQ: PDSB). According to a report from Global Market Insights, the global oncology market was estimated at US$345.1 billion in 2025, and while growing at an impressive 10.8% CAGR, is projected to reach US$866.1 billion by 2034 — with $377.1 billion of that coming from the USA alone. Even more optimistic is a report from Vision Research Reports, which sees the global cancer drug sector surpassing US$900 billion in sales by 2034. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset, pelareorep. In its latest Q2 2025 report, the company confirmed it has begun formal discussions with the U.S. Food and Drug Administration (FDA) aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025. For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine's most challenging cancer types. "We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year," said Jared Kelly, CEO of Oncolytics. "As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors." The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically "cold" tumors—those typically invisible to the immune system—into "hot" tumors that can respond to immunotherapy. In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a 9.2% historical benchmark for standard chemotherapy alone. Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep's dual mechanism: it both replicates within cancer cells and activates the body's immune response against tumors. "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from over 1,100 patients across multiple studies, has solidified the company's decision to prioritize this indication. Oncolytics' execution-focused strategy is being led by Jared Kelly and Andrew Aromando, who both played key roles in Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution. Regulatory advantages are already in place to accelerate development. Pelareorep holds Fast Track and Orphan Drug designations for pancreatic cancer from the FDA, meaning the agency has already recognized both the drug's potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program's attractiveness to potential pharmaceutical partners. The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a five-year survival rate of less than 14%. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep's immune-activating mechanism particularly promising for this underserved patient population. Back in July, Oncolytics hosted a key opinion leader event featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep's mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment. With this latest milestone, Oncolytics is entering a phase where FDA feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company's proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep's market potential in mPDAC. The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution, Oncolytics is positioning pelareorep for a pivotal test in one of oncology's most challenging and underserved markets. In other recent industry developments and happenings in the market include: ProPhase Labs, Inc. (NASDAQ: PRPH) announced it received a U.S. patent for its BE-Smart test that can detect early signs of Barrett's esophageal cancer, a deadly disease that kills most patients because it's usually caught too late. The test works with simple brush and forceps biopsies and achieved over 95% accuracy in clinical testing, potentially allowing doctors to catch this cancer when it's still treatable. "This achievement, coming on the heels of our BE-Smart ™ validation demonstrating greater than a 95% technical success rate and dual compatibility with both brush and forceps biopsies, solidifies our leadership in medical innovation and brings us one step closer to transforming early detection and treatment strategies for this serious condition," said Ted Karkus, CEP of ProPhase. "With this newly issued patent, we believe we are well positioned to accelerate commercialization and broaden clinical access to BE-Smart." ProPhase's breakthrough could save thousands of lives by identifying patients at high risk for esophageal cancer before the disease becomes incurable, representing a major advancement in early cancer detection. IO Biotech, Inc. (NASDAQ: IOBT) recently announced that its experimental cancer vaccine (Cylembio) meaningfully extended the time before advanced melanoma patients got worse, with patients living 19.4 months without disease progression compared to 11 months for those on standard treatment alone. The vaccine works by training the immune system to attack both cancer cells and the cells that help tumors hide from treatment, and it showed particularly strong results in patients whose tumors were PD-L1 negative and unlikely to respond to current immunotherapies. "In this study, we observed a highly encouraging improvement in progression free survival and consistent trend in overall survival in patients treated with Cylembio," said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. "The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data." IO Biotech plans to meet with the FDA this fall to discuss approval for this treatment that could become a new standard of care for the deadliest form of skin cancer. Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) reported progress on its experimental breast cancer pill called palazestrant, which is designed to completely block estrogen signals that fuel most breast cancers and is currently being tested in two large Phase 3 trials expected to finish in 2026. "Having achieved regulatory alignment on the selected dose for our pivotal palazestrant program during the second quarter, we are focused on accelerating enrollment in OPERA-01, which is on track for top-line data in the second half of 2026," said Sean P. Bohen, M.D., Ph.D., President and CEO of Olema. "Palazestrant's demonstrated activity and combinability with multiple compounds offers the potential for it to become a best-in-class, backbone endocrine therapy for metastatic breast cancer." The company is also developing OP-3136, a pill that targets a different pathway cancer cells use to grow and spread, with early results expected in 2026. Olema's drugs are designed to work where current treatments fail, potentially offering hope to the thousands of breast cancer patients whose tumors eventually become resistant to existing therapies. PDS Biotechnology Corporation (NASDAQ: PDSB) reported promising results from a colorectal cancer study where its experimental treatment achieved impressive response rates, leading to expansion of the trial to treat more patients with this hard-to-treat cancer. "Our second quarter of 2025 and recent weeks have been a productive period for PDS Biotech, highlighted by the continued progress in our VERSATILE-003 Phase 3 clinical trial," said Frank Bedu-Addo, Ph.D., President and CEO of PDS Biotech. "We look forward to publishing the full data set for this trial later this year, as we continue to progress our VERSATILE-003 trial, the only registrational stage trial specifically targeting HPV16-positive HNSCC patients." The company's lead program targets head and neck cancers caused by HPV, the same virus that is a major cause of cervical cancer, and is currently being tested in the only late-stage trial specifically designed for these patients. PDS Biotech's approach uses its immune-boosting technology to help the body's natural defenses better recognize and destroy cancer cells, potentially offering new hope for patients with limited treatment options. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.


Winnipeg Free Press
2 minutes ago
- Winnipeg Free Press
Toronto FC gets US$175,000 in general allocation money from Inter Miami
TORONTO – Toronto FC and Inter Miami traded for roster resources on Thursday. TFC got US$175,000 in general allocation money for this year in the deal. In return, Inter Miami received an international roster spot for this season. It's the latest in a series of similar deals Toronto FC has made to stockpile GAM. The most recent came on Wednesday when Toronto sent midfielder Matty Longstaff to CF Montreal for forward Jules-Anthony Vilsaint and $225,000 in 2025 GAM. Thursdays Keep up to date on sports with Mike McIntyre's weekly newsletter. TFC will also get a conditional $50,000 in 2026 GAM from that deal, depending on Longstaff's roster status next year. This report by The Canadian Press was first published Aug. 14, 2025.


Toronto Star
32 minutes ago
- Toronto Star
Top NAHREP Agent, Vivian Lesny, Joins eXp Realty to Champion Community, Culture, and Collaboration
BELLINGHAM, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) — eXp Realty®, 'the most agent-centric real estate brokerage on the planet™' and the core subsidiary of eXp World Holdings, Inc. (Nasdaq: EXPI), today announced that top-producing Southern California agent and NAHREP Top 250 Latina leader, Vivian Lesny, has joined its growing global network. With more than two decades in real estate, Lesny surpassed $70 million in sales in 2024 and has closed more than 88 transactions in a single year, all while maintaining a consistent presence among NAHREP's Top 250 Latino Agents in the U.S. and Top 100 in the Southwest. A seasoned professional and native Culver City resident with deep roots in Marina Del Rey, Playa Vista, Playa del Rey and Westchester, Lesny is known not just for production, but for purpose. Her high-performing business, including a flipping portfolio that accounts for 35% of her income, is matched by her commitment to community and equity in homeownership.